These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3390390)

  • 1. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
    Kimura A; Katoh O; Kuramoto A
    Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of PDGF on myeloproliferative disorders].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
    Katoh O; Kimura A; Itoh T; Kuramoto A
    Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
    Katoh O; Kimura A; Kuramoto A
    Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
    Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
    Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
    Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
    Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast colony-forming cells with high sensitivity to serum mitogen(s) exist in bone marrow of patients with chronic myelocytic leukemia.
    Kimura A; Katoh O; Hyodo H; Kusumi S; Kuramoto A
    Eur J Haematol; 1990 May; 44(5):291-5. PubMed ID: 2369940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
    Dalley A; Smith JM; Reilly JT; Neil SM
    Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders.
    Castro-Malaspina H; Gay RE; Jhanwar SC; Hamilton JA; Chiarieri DR; Meyers PA; Gay S; Moore MA
    Blood; 1982 May; 59(5):1046-54. PubMed ID: 7042002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia.
    Yonekura S; Nagao T; Arimori S
    Br J Haematol; 1985 Sep; 61(1):93-9. PubMed ID: 3863668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
    Frisch B; Bartl R; Burkhardt R; Jäger K
    Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts.
    Kimura A; Katoh O; Hyodo H; Kuramoto A
    Br J Haematol; 1989 Aug; 72(4):486-91. PubMed ID: 2789074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance.
    Cervantes F; Pereira A; Marti JM; Feliu E; Rozman C
    Br J Haematol; 1988 Nov; 70(3):279-82. PubMed ID: 3207625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
    Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
    J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
    Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
    Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
    Wróbel T; Mazur G; Surowiak P; Wolowiec D; Jelen M; Kuliczkowsky K
    Pathol Oncol Res; 2003; 9(3):170-3. PubMed ID: 14530810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reversible defect of platelet PDGF content in myeloproliferative disorders.
    Baglin TP; Price SM; Boughton BJ
    Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.
    Gilbert HS; Praloran V; Stanley ER
    Blood; 1989 Sep; 74(4):1231-4. PubMed ID: 2669997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.